WO2006024689A1 - Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency - Google Patents

Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency Download PDF

Info

Publication number
WO2006024689A1
WO2006024689A1 PCT/FI2005/000333 FI2005000333W WO2006024689A1 WO 2006024689 A1 WO2006024689 A1 WO 2006024689A1 FI 2005000333 W FI2005000333 W FI 2005000333W WO 2006024689 A1 WO2006024689 A1 WO 2006024689A1
Authority
WO
WIPO (PCT)
Prior art keywords
testosterone
hypogonadism
syndrome
deficiency
estrogen receptor
Prior art date
Application number
PCT/FI2005/000333
Other languages
English (en)
French (fr)
Inventor
Taru Blom
Janne Komi
Risto Lammintausta
Original Assignee
Hormos Medical Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20041216A external-priority patent/FI20041216A0/fi
Application filed by Hormos Medical Ltd. filed Critical Hormos Medical Ltd.
Priority to EP05771627A priority Critical patent/EP1786408A4/en
Priority to BRPI0514701-8A priority patent/BRPI0514701A/pt
Priority to AU2005279178A priority patent/AU2005279178A1/en
Priority to CA002578852A priority patent/CA2578852A1/en
Priority to MX2007002606A priority patent/MX2007002606A/es
Priority to JP2007529372A priority patent/JP2008511615A/ja
Publication of WO2006024689A1 publication Critical patent/WO2006024689A1/en
Priority to NO20071160A priority patent/NO20071160L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Definitions

  • This invention relates to a method for treatment or prevention of androgen deficiency in a male individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator (SERM).
  • SERM selective estrogen receptor modulator
  • the invention concerns further methods for treatment or prevention of diseases or disorders caused by said androgen deficiency.
  • Masculine sex hormones are responsible for the development of the masculine sex characteristics. Furthermore, they are required for reproduction.
  • the main element of the androgens is testosterone, which is imperative for the development and the function of the internal and external masculine sex organs, which has a supportive influence regarding muscle growth, which determines the distribution and the density of hair growth, which has a positive influence with respect to the production of erythrocytes and with respect to the distribution of erythropoietin and the cognitive functions.
  • a shortage of testosterone may be classified into two principle forms, which are designated primary and secondary hypogonadism. Diseases based on testosterone shortage include for instance osteoporosis, muscle atrophy, senescence outfall symptoms,

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/FI2005/000333 2004-09-03 2005-07-20 Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency WO2006024689A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP05771627A EP1786408A4 (en) 2004-09-03 2005-07-20 USE OF A SELECTIVE ESTROGEN RECEPTOR MODULATOR IN THE MANUFACTURE OF A PHARMACEUTICAL PREPARATION USED IN A METHOD OF TREATING OR PREVENTING ENDROGENIC INJURIES
BRPI0514701-8A BRPI0514701A (pt) 2004-09-03 2005-07-20 uso de um modulador do receptor de estrogênio seletivo, ou um isÈmero, mistura de isÈmero, metabólito ou um sal farmaceuticamente aceitável do mesmo
AU2005279178A AU2005279178A1 (en) 2004-09-03 2005-07-20 Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency
CA002578852A CA2578852A1 (en) 2004-09-03 2005-07-20 Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency
MX2007002606A MX2007002606A (es) 2004-09-03 2005-07-20 Uso de un modulador del receptor selectivo a estrogeno para la elaboracion de una preparacion farmaceutica para uso en un metodo para el tratamiento o prevencion de la deficiencia de androgenos.
JP2007529372A JP2008511615A (ja) 2004-09-03 2005-07-20 アンドロゲン欠乏症の治療法または予防法に使用する医薬調製物の製造に用いるエストロゲン受容体選択的調節物質
NO20071160A NO20071160L (no) 2004-09-03 2007-03-01 Anvendelse av en selektiv ostrogenreseptormodulator for fremstilling av et farmasoytisk preparat for anvendelse i en fremgangsmate for behandling eller forebygging av androgenmangel

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60690704P 2004-09-03 2004-09-03
US60/606,907 2004-09-03
FI20041216 2004-09-21
FI20041216A FI20041216A0 (fi) 2004-09-21 2004-09-21 Menetelmä androgeenivajeen hoitoon tai estoon

Publications (1)

Publication Number Publication Date
WO2006024689A1 true WO2006024689A1 (en) 2006-03-09

Family

ID=35999733

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2005/000333 WO2006024689A1 (en) 2004-09-03 2005-07-20 Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency

Country Status (10)

Country Link
EP (1) EP1786408A4 (es)
JP (1) JP2008511615A (es)
KR (1) KR20070059110A (es)
AU (1) AU2005279178A1 (es)
BR (1) BRPI0514701A (es)
CA (1) CA2578852A1 (es)
MX (1) MX2007002606A (es)
NO (1) NO20071160L (es)
RU (1) RU2007112114A (es)
WO (1) WO2006024689A1 (es)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2518039A1 (en) 2007-02-14 2012-10-31 Hormos Medical Ltd. Method for the preparation of therapeutically valuable triphenylbutene derivatives
US20130217696A1 (en) * 2007-06-13 2013-08-22 Quatrx Pharmaceuticals Company Methods for the treatment of erectile dysfunction using fispemifene
US9078871B2 (en) 2010-06-10 2015-07-14 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2015135061A1 (en) 2014-03-10 2015-09-17 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm
US9187460B2 (en) 2011-12-14 2015-11-17 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2016108172A1 (en) 2014-12-29 2016-07-07 Olon S.P.A. Process for the preparation of ospemifene and fispemifene
WO2023175010A1 (fr) * 2022-03-15 2023-09-21 Centre D'etude Des Cellules Souches (Cecs) Utilisation du bazedoxifene pour augmenter la survie musculaire

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0793961A1 (en) * 1996-02-28 1997-09-10 Pfizer Inc. Use of droloxifene for the manufacture of a medicament for increasing serum levels of testosterone
WO2001036360A1 (en) * 1999-11-16 2001-05-25 Hormos Medical Corporation Triphenylalkene derivatives and their use as selective estrogen receptor modulators
WO2001091744A1 (en) * 2000-05-26 2001-12-06 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
US6512002B2 (en) * 2000-01-12 2003-01-28 Pfizer Inc. Methods of treatment for premature ejaculation in a male
WO2003047504A2 (en) * 2001-11-29 2003-06-12 Gtx Inc. Prevention and treatment of androgen-deprivation induced osteoporosis
WO2003072092A1 (en) * 2002-02-21 2003-09-04 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0793961A1 (en) * 1996-02-28 1997-09-10 Pfizer Inc. Use of droloxifene for the manufacture of a medicament for increasing serum levels of testosterone
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
WO2001036360A1 (en) * 1999-11-16 2001-05-25 Hormos Medical Corporation Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US6512002B2 (en) * 2000-01-12 2003-01-28 Pfizer Inc. Methods of treatment for premature ejaculation in a male
US20030114440A1 (en) * 2000-01-12 2003-06-19 Lee Andrew G. Compositions and methods of treatment for conditions responsive to testosterone elevation
WO2001091744A1 (en) * 2000-05-26 2001-12-06 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
WO2003047504A2 (en) * 2001-11-29 2003-06-12 Gtx Inc. Prevention and treatment of androgen-deprivation induced osteoporosis
WO2003072092A1 (en) * 2002-02-21 2003-09-04 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 133:26826, KE H.Z. ET AL: "Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat" XP003010330 *
DATABASE BIOSIS [online] STEINER M.S. ET AL: "Selective estrogen receptor modulators for the chemoprevention of prostate cancer", XP003010322, Database accession no. (prev200100240383) *
ENDOCRINOLOGY, vol. 141, no. 4, 2000, pages 1338 - 1344 *
See also references of EP1786408A4 *
UROLOGY, vol. 57, no. 4A, April 2001 (2001-04-01), pages 68 - 72 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2518039A1 (en) 2007-02-14 2012-10-31 Hormos Medical Ltd. Method for the preparation of therapeutically valuable triphenylbutene derivatives
EP2821385A2 (en) 2007-02-14 2015-01-07 Hormos Medical Ltd. Method for the preparation of therapeutically valuable triphenylbutene derivatives
US20130217696A1 (en) * 2007-06-13 2013-08-22 Quatrx Pharmaceuticals Company Methods for the treatment of erectile dysfunction using fispemifene
US10500166B2 (en) * 2007-06-13 2019-12-10 Quatrx Pharmaceuticals Methods for the treatment of erectile dysfunction using fispemifene
US9078871B2 (en) 2010-06-10 2015-07-14 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
US9187460B2 (en) 2011-12-14 2015-11-17 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
EP3116510A4 (en) * 2014-03-10 2017-08-16 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
WO2015135061A1 (en) 2014-03-10 2015-09-17 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm
US10548903B2 (en) 2014-03-10 2020-02-04 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
WO2016108172A1 (en) 2014-12-29 2016-07-07 Olon S.P.A. Process for the preparation of ospemifene and fispemifene
WO2023175010A1 (fr) * 2022-03-15 2023-09-21 Centre D'etude Des Cellules Souches (Cecs) Utilisation du bazedoxifene pour augmenter la survie musculaire

Also Published As

Publication number Publication date
BRPI0514701A (pt) 2008-06-24
NO20071160L (no) 2007-05-25
CA2578852A1 (en) 2006-03-09
AU2005279178A1 (en) 2006-03-09
EP1786408A4 (en) 2010-07-28
MX2007002606A (es) 2007-05-15
JP2008511615A (ja) 2008-04-17
EP1786408A1 (en) 2007-05-23
RU2007112114A (ru) 2008-10-10
KR20070059110A (ko) 2007-06-11

Similar Documents

Publication Publication Date Title
Begam et al. Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review
Komm et al. An overview of current and emerging SERMs
EP1786408A1 (en) Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency
EP2106212B1 (en) Nuclear receptor binding agents
Suh et al. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer
US9561238B2 (en) Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
FI118755B (fi) Trifenyylietyleenejä käytettäväksi osteoporoosin ehkäisyyn ja hoitoon
KR101403893B1 (ko) 4,17β-디히드록시안드로스트-4-엔-3-온에 대한 신규한 용도들
US20060293294A1 (en) Method for treatment or prevention of androgen deficiency
EP2819676B1 (en) Combination therapy for treating androgen deficiency
Bojkova et al. Metformin in chemically-induced mammary carcinogenesis in rats
JP6025301B2 (ja) 治療上の使用のためのｃ−１９ステロイド
Clarke et al. New selective estrogen and androgen receptor modulators
Ray et al. Development of estrogen antagonists as pharmaceutical agents
CN1168448C (zh) 预防和/或治疗乳腺癌的含类固醇芳香酶抑制剂的药物
CN1893955A (zh) 用于预防和治疗激素依赖性疾病的包含孕酮受体拮抗剂和纯抗雌激素的组合物
JP2001505574A (ja) １７α−ジヒドロエキレニンを使用した神経退化および認識機能障害の予防方法
Levin Fulvestrant
Kumar et al. Antiestrogen therapy for Breast Cancer: An overview.
US20230210870A1 (en) Methods of treating female health conditions related to sex hormones
Laugier et al. Dissociated effects of tamoxifen on growth and on progesterone receptor induction in quail oviduct
Buzdar Hormonal therapy in early and advanced breast cancer
Zitzmann LONGTERM-TREATMENT OF OVERWEIGHT OR OBESE HYPOGONADAL MEN USING INTRAMUSCULAR TESTOSTERONE UNDECANOATE: EXPERIENCE OF 4-7 YEARS
Poirier et al. Chemical synthesis, plasmatic concentration and antisulfatase activity in mice and rats of a tetrahydroisoquinoline derivative
Rivera-Guevara et al. New Tamoxifen-based Strategies in Cancer Research

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 200580029252.6

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2005279178

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/002606

Country of ref document: MX

Ref document number: 2578852

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007529372

Country of ref document: JP

Ref document number: 927/CHENP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005771627

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005279178

Country of ref document: AU

Date of ref document: 20050720

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005279178

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077006922

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007112114

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005771627

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0514701

Country of ref document: BR